{"id":29841,"date":"2014-08-29T07:19:07","date_gmt":"2014-08-29T11:19:07","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=29841"},"modified":"2014-08-29T07:19:07","modified_gmt":"2014-08-29T11:19:07","slug":"is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841","title":{"rendered":"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)?"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/29\/2014 (wallstreetpr) \u2013\u00a0Several analysts are giving a second thought on their ratings on <strong>Keryx Biopharmaceuticals (NASDAQ:KERX)<\/strong>. Maxim Group has got a \u201c<a href=\"http:\/\/sleekmoney.com\/keryx-biopharmaceuticals-given-buy-rating-at-maxim-group-kerx\/7831\/\">buy<\/a>\u201d rating on Keryx stocks. FBR Capital Markets have got a \u201cmarket perform\u201d rating on Keryx with a price target of $16.00. As of now, Keryx shares are trading well above their target price. Analysts at Mizuho have got more optimistic target on Keryx shares. They have a target of $30.00 for Keryx Biopharmaceuticals. Keryx have got eight \u201cbuy\u201d rating and one \u201chold\u201d rating with a consensus target price of $22.89. The stock has gained more than 30% in last three months.<\/p>\n<p style=\"text-align: justify;\"><strong>The performance<\/strong><\/p>\n<p style=\"text-align: justify;\">Keryx Biopharmaceuticals (NASDAQ:KERX) reported a net loss of $22.4 million comparable to a net loss of $11.4 million in 2Q2013. It included non-compensation expense of $2.6 million done in equity and investment grants. The R&amp;D expenses came at $10.3 million, up by $3.1 million as compared to 2Q2013. Keryx is working on Zerenex development plan and, therefore, the costs related with the capacity expansion and manufacturing of pre-launch inventory led to the higher R&amp;D expenses in 2Q2013.<\/p>\n<p style=\"text-align: justify;\">The G&amp;A expenses came at $12.3 million, up by $8 million as compared to 2Q2013. The expenses related to pre-commercial activities of Zerenex led to the higher G&amp;A expenses. The cash and cash equivalents with short-term investments came at $137.1 million in 2Q2013 comparable to $55.7 million in the last quarter.<\/p>\n<p style=\"text-align: justify;\"><strong>The management view<\/strong><\/p>\n<p style=\"text-align: justify;\">Ron Bentsur, the CEO, talked about the progress made on the review of the NDA. He said that Keryx Biopharmaceuticals (NASDAQ:KERX) have successfully answered to all the CMC related questions asked by the FDA in month of May. They are just one month away from PDUFA action goal date, and FDA has said that Keryx will receive a draft label soon. Keryx is delighted with the progress made with its Zerenex program which will soon make its way in the U.S. markets.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/29\/2014 (wallstreetpr) \u2013\u00a0Several analysts are giving a second thought on their ratings on Keryx Biopharmaceuticals (NASDAQ:KERX). Maxim Group has got a \u201cbuy\u201d rating [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":41704,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3545,3546],"stock_ticker":[],"class_list":["post-29841","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-keryx-biopharmaceuticals-nasdaqkerx","tag-nasdaqkerx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)? - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)? - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/29\/2014 (wallstreetpr) \u2013\u00a0Several analysts are giving a second thought on their ratings on Keryx Biopharmaceuticals (NASDAQ:KERX). Maxim Group has got a \u201cbuy\u201d rating [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-29T11:19:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"275\" \/>\n\t<meta property=\"og:image:height\" content=\"183\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)?\",\"datePublished\":\"2014-08-29T11:19:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg\",\"keywords\":[\"Keryx Biopharmaceuticals (NASDAQ:KERX)\",\"NASDAQ:KERX\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841\",\"name\":\"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)? - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg\",\"datePublished\":\"2014-08-29T11:19:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg\",\"width\":275,\"height\":183},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)? - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841","og_locale":"en_US","og_type":"article","og_title":"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)? - Wall Street PR","og_description":"Boston, MA 08\/29\/2014 (wallstreetpr) \u2013\u00a0Several analysts are giving a second thought on their ratings on Keryx Biopharmaceuticals (NASDAQ:KERX). Maxim Group has got a \u201cbuy\u201d rating [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-29T11:19:07+00:00","og_image":[{"width":275,"height":183,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)?","datePublished":"2014-08-29T11:19:07+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg","keywords":["Keryx Biopharmaceuticals (NASDAQ:KERX)","NASDAQ:KERX"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841","url":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841","name":"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)? - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg","datePublished":"2014-08-29T11:19:07+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/WallStreet10-1.jpg","width":275,"height":183},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/is-it-time-to-buy-keryx-biopharmaceuticals-nasdaqkerx-29841#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Is It Time To Buy Keryx Biopharmaceuticals (NASDAQ:KERX)?"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=29841"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/41704"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=29841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=29841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=29841"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=29841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}